Navigation Links
Supercomputing equipment to advance the frontiers of computational biology

Researchers at Rensselaer Polytechnic Institute will continue to advance the frontiers of computational science with the help of IBM's Blue Gene supercomputer. Awarded under IBM's Shared University Research (SUR) program, this Blue Gene will complement the $100 million partnership between Rensselaer, IBM, and New York state to create one of the world's most powerful university-based supercomputing centers.

The equipment will provide a resource for scientists to gain experience with the Blue Gene computing environment, while also supporting a project to develop new simulation technologies for understanding biological systems. The work will help researchers develop algorithms and software that run efficiently on Blue Gene technology, which is a key part of the new Computational Center for Nanotechnology Innovations (CCNI).

This $2.23 million gift of IBM equipment counts toward the $1.4 billion Renaissance at Rensselaer campaign.

"This award further advances the strong partnership between IBM and Rensselaer to develop a leading-edge, high-performance computational capability," said Rensselaer President Shirley Ann Jackson. "It will allow our faculty and students to take the lead in research that will enable key nanotechnology innovations in the fields of energy, biotechnology, arts, and medicine."

As biology becomes a more quantitative field, researchers need new simulation technologies to understand how proteins, DNA, and other biological systems behave at the molecular level, according to the Rensselaer research team. The new SUR award is designed to help develop simulations for prototyping medical devices in "virtual patients," with potential applications in targeted drug delivery systems such as drug eluting stents, transdermal patches, and inhalers.

To be successful, these simulations must run efficiently and effectively on the latest generation of high-performance computing equipment. The project will help researcher s develop critical computational biology tools that operate on the Blue Gene system, with the goal of making these available to a broad community of users.

The project's principal investigators at Rensselaer are Angel Garcia, senior constellation chaired professor in biocomputation and bioinformatics; Mark Shephard, the Samuel A. and Elisabeth C. Johnson Jr. Professor of Engineering and director of the Scientific Computation Research Center; Shekhar Garde, the Elaine and Jack S. Parker Career Development Professor of Chemical and Biological Engineering; and Kenneth Jansen, associate professor of mechanical, aerospace, and nuclear engineering.

The new Blue Gene system consists of a single rack with 1,024 dual processor compute nodes, 32 I/O nodes, a service node, a front-end node, and multiple terabytes of SAN-based disk storage.

Announced in May 2006, the Computational Center for Nanotechnology Innovations (CCNI) is a $100 million partnership between Rensselaer, IBM, and New York state to create one of the world's most powerful university-based supercomputing centers, and a top supercomputing center of any kind in the world. The center is designed to help continue the impressive advances in shrinking device dimensions seen by electronics manufacturers, and to enable key nanotechnology innovations in the fields of energy, biotechnology, arts, and medicine. Learn more at the CCNI Web site: http://rpi.edu/research/ccni/index.html.
'"/>

Source:Rensselaer Polytechnic Institute


Related biology news :

1. Aptamer-based Biosensor screens Air Force personnel and equipment
2. A step toward the $1,000 personal genome using readily available lab equipment
3. Research advances quest for HIV-1 vaccine
4. Inexpensive, mass-produced genes core of synthetic biology advances at UH
5. Study of genomic DNA leads to new advances in cancer diagnostics
6. Molecular models advance the fight against malaria
7. Researchers test new therapy for advanced melanoma
8. Agilent Technologies introduces advanced zebrafish, mouse microarrays for stem cell and developmental biology research
9. Major advance made on DNA structure
10. Wild grasses and man-made wheats advance research capabilities
11. Gene therapy advance treats hemophilia in mouse models

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... March 23, 2017 The report "Gesture Recognition and Touchless ... and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is ... of 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
(Date:3/20/2017)... 2017 PMD Healthcare announces the release of ... Management System (WMS), a remote, real-time lung health monitoring ... Healthcare is a Medical Device, Digital Health, and Chronic ... creating innovative solutions that empower people to improve their ... PMD developed the first ever personal spirometer, Spiro PD, ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring ... of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. ... activities. , “Dr. Floyd’s career has spanned 30 years in the chemicals and ...
(Date:3/22/2017)... , March 22, 2017 Good Start Genetics, ... has eclipsed the 130 million covered lives mark through ... of Texas . With newly signed ... continues to enjoy strong payor acceptance based on the ... programs and genetic counseling, its industry-leading customer care and ...
(Date:3/22/2017)... - FACIT announced a seed stage investment in ... created by FACIT focused on developing a portfolio ... non-dilutive capital, achieves a targeted $3.0M financing for ... to accelerate the nomination of a candidate drug ... a strategic partnership for clinical trials in patients ...
Breaking Biology Technology: